ENLV שווי כולל של נכסי החברה Enlivex Therapeutics, Ltd.

Enlivex Therapeutics (ENLV) is developing a non-cyclical emergency medicine vertical where the demand for sepsis treatment remains independent of seasonal or economic fluctuations. The market share price trend on the GURU.Markets platform shows that total assets amount to 1177.37. The company is creating a unique macrophage modification system that enables the body to independently suppress inflammation in severe pathologies and tumors, which is set to become a new standard in intensive care medicine.

Total assets represent the aggregate value of all corporate resources, calculated reversely via return on assets (ROA) to assess the fundamental stability of the business. Analyzing this total asset calculation allows an investor to compare the asset base of Enlivex Therapeutics (ENLV) with the potential for pricing power that the company gains through the creation of a unique cell reprogramming technology for sepsis therapy.